ATLANTA is the first ever randomised control trial looking at using focal therapy alongisde traditional surgery and radiotherapy to improve survival in men with metastatic prostate cancer.
ATLANTA will be the largest cytoreductive local treatment trial in the world.
A team of experts led by Professor Hashim Ahmed, based at Imperial College London, will be conducting this novel study.
This trial is funded by the Wellcome Trust charity and is managed by Imperial Clinical Trials Unit (ICTU).
Men in the UK are diagnosed with prostate cancer each year
3 in 10 prostate cancer diagnoses are already advanced
Suggests treating the prostate tumour even in already advanced disease may significantly improve survival
Will test this new research with standard and new cutting edge prostate therapies not yet available in the NHS